Background: Fenofibrate is having a broad spectrum lipid-lowering activity that produces substantial reductions in the fatty components. The drug belongs to BCS Class-II and therefore in the majority of the cases, low pharmacodynamic potentials have been perceived and it requires serious improvement in the aqueous solubility. For the marked solubility enhancement of drugs, solid dispersions are an impressive approach. Objective: The current research emphasized on development of fenofibrate solid dispersions by employing the polymer PEG 6000 in the ratio of 1:1 w/w - 1:3 w/w using the fusion method/melting method/solvent evaporation method for enhancing the aqueous solubility that will directly affect the dissolution process and ultimately the therapeutic bioavailability. Methods: The fabricated solid dispersions were characterized for production yield, drug content, bulk density, tapped density, Carr__ampersandsignrsquo;s index, Hausner__ampersandsignrsquo;s ratio, angle of repose, and cumulative drug release. The transformation from crystalline nature to the amorphous form was characterized by DSC and XRD techniques. The optimized solid dispersion formulations were further loaded into the capsule and the content uniformity, drug content, disintegration time, and cumulative drug release in both the medium for 1 hr duration were investigated. Results: The physical mixtures exhibited the lowest drug release in the range 15%-26% at increasing polymeric ratios while the highest drug release was observed in solid dispersion batch prepared by fusion method (22.56%-34.89%). FT-IR studies indicated no incompatibilities between the drug and the polymer. Conclusion: This interesting investigation opened new avenues for the pharmacotherapeutic perspective of this drug in the upcoming future, both pharmacodynamically and pharmacokinetically by enhancing the aqueous solubility